Overview
- 4 inspections across 4 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2024-04-30.
At a glance
Inspections
4
Sites
4
Observations
0
Career since
Aug 2023
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| AUTOLUS LIMITED | 30 Apr 2024 | Biologics | On file |
| Novartis Pharma Stein AG | 20 Nov 2023 | Biologics | |
| GI Accelerate Memphis LLC | 25 Aug 2023 | Biologics | On file |
| ROSLIN CELL THERAPIES LIMITED | 4 Aug 2023 | Biologics | On file |
Sites inspected
AUTOLUS LIMITEDStevenage, United Kingdom1 insp.
Novartis Pharma Stein AGStein Ag, Switzerland1 insp.
GI Accelerate Memphis LLCMemphis, United States1 insp.
ROSLIN CELL THERAPIES LIMITEDEdinburgh, United Kingdom1 insp.
Co-investigators
Investigators who share inspections with this person.
Kula N Jha2 shared
Kathleen R Jones2 shared
Zhaohui Ye2 shared
Andrew E Timmons1 shared
Hoda N Abadeer1 shared
Carl A Perez1 shared
Gregory A Price1 shared
Prajakta A Varadkar1 shared
Donald B Ertel1 shared
Wei Wang1 shared
Full investigator report
Get the verbatim findings behind Jessica Chery's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site